Cellectis S.A Long Term Debt 2015-2025 | CLLS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cellectis S.A long term debt from 2015 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cellectis S.A long term debt from 2015 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$217.3B
Amgen (AMGN)	$160.8B
Gilead Sciences (GILD)	$136.6B
Vertex Pharmaceuticals (VRTX)	$120.6B
Bristol Myers Squibb (BMY)	$96B
CSL (CSLLY)	$78.5B
GSK (GSK)	$78.4B
Regeneron Pharmaceuticals (REGN)	$59.2B
Alnylam Pharmaceuticals (ALNY)	$42.1B
Argenex SE (ARGX)	$35.4B
BioNTech SE (BNTX)	$27B
Royalty Pharma (RPRX)	$20B
Insmed (INSM)	$19.8B
Biogen (BIIB)	$18.8B
Illumina (ILMN)	$15.3B
Genmab (GNMSF)	$14.2B
Genmab (GMAB)	$14B
Incyte (INCY)	$13.4B
Moderna (MRNA)	$12.4B
Exelixis (EXEL)	$12.2B
BioMarin Pharmaceutical (BMRN)	$11.2B
QIAGEN (QGEN)	$10.7B
Ascendis Pharma (ASND)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Exact Sciences (EXAS)	$10.1B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$8.1B
Roivant Sciences (ROIV)	$7.8B
Regencell Bioscience Holdings (RGC)	$7.6B